All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by AbbVie, BeOne Medicines, Johnson & Johnson, Roche and sobi, and supported through educational grants from Bristol Myers Squibb, Incyte and Lilly. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lymphoma & CLL content recommended for you
Nathan FowlerFollowing this year's American Society of Clinical Oncology (ASCO) Annual Meeting and during the 25th Congress of the European Hematology Association (EHA), the Lymphoma Hub spoke to Nathan Fowler, MD Anderson Cancer Center, Houston, US. We asked: What was new in indolent non-Hodgkin lymphoma at ASCO and EHA 2020?
Nathan Fowler highlights abstracts of particular interest from ASCO, including a study evaluating the chimeric antigen receptor T-cell treatment, axicabtagene ciloleucel, for indolent non-Hodgkin lymphoma, a long-term follow up of the GALLIUM trial, and the interim analysis of the MAGNIFY trial. Nathan Fowler also outlines abstracts to watch from EHA, including studies evaluating zanubrutinib for the treatment of marginal cell lymphoma and those investigating the PI3-kinase delta inhibitor, ME-401, for the treatment of relapsed or refractory disease.
What was new in indolent NHL at ASCO and EHA?
Your opinion matters
In your experience, when do most CRS/ICANS events occur after lisocabtagene maraleucel infusion?